Please login to the form below

Not currently logged in
Email:
Password:

liver cancer

This page shows the latest liver cancer news and features for those working in and with pharma, biotech and healthcare.

Chinese biotechs aim PD-L1 antibody at hepatitis B

Chinese biotechs aim PD-L1 antibody at hepatitis B

Cancer therapies could help boost patient's immune system. Checkpoint inhibitors are already making a big impact in cancer, but two Chinese biotechs want to explore their activity in viral diseases, ... HBV can be treated effectively with antiviral drugs

Latest news

  • Roche's O’Day swaps big pharma for big biotech Roche's O’Day swaps big pharma for big biotech

    including liver diseases and particularly cancer, very much Roche’s main stamping ground.

  • New leader at Medivir after setbacks New leader at Medivir after setbacks

    PD-1 drug Keytruda (pembrolizumab) in lung cancer. ... Along with remetinostat, Medivir’s clinical pipeline includes birinapant for solid tumours, MIV-818 for liver cancer and MIV-711 for osteoarthritis.

  • CRUK forges £30m ‘post-Brexit’ R&D alliance CRUK forges £30m ‘post-Brexit’ R&D alliance

    One UK project – called HUNTER - is getting £5m to look into immunotherapies for liver cancer and will be led by Newcastle University. ... It aims to develop a network of EU and UK clinicians and scientists specialising in hepatocellular carcinoma (HCC

  • Eisai’s Lenvima wins European liver cancer indication Eisai’s Lenvima wins European liver cancer indication

    It is now set as a first-line treatment for adults who have received no prior systemic therapy for advanced or unresectable hepatocellular carcinoma (HCC), a type of liver cancer that ... Liver cancer is the second leading cause of cancer-related death,

  • ACT immunotherapy cures terminal breast cancer patient ACT immunotherapy cures terminal breast cancer patient

    Judy Perkins had hormone receptor-positive breast cancer that had spread to her liver and other organs and had exhausted all other treatment options, including several rounds of chemotherapy, and none ... The new study suggests that barrier could be

More from news
Approximately 10 fully matching, plus 100 partially matching documents found.

Latest Intelligence

  • Making Europe a leader in bioscience: boosting trust and opening minds Making Europe a leader in bioscience: boosting trust and opening minds

    This public-private research alliance is aimed at improving survival rates in hepatocellular carcinoma (the primary cancer of the liver). ... of this cancer.

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    13 new targeted medicines that block the growth and spread of cancer by interfering with specific molecular targets. ... Other oncolytic viruses are coming through the pipeline, including SillaJen/Transgene’s Pexa-Vec for liver cancer and other solid

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    Co-development was another area in which major pharma firms were active, particularly Lilly, which enlarged its work with Boehringer Ingelheim to add in breast cancer programmes and closed a ... NASH and biosimilars. One therapeutic indication that could

  • Pharma deals in April 2015 Pharma deals in April 2015

    The treatment combines an antibody engineered to target CD19 with the cancer-killing agent maytansinoid. ... Menarini AP will be responsible for the clinical development, regulatory approval and commercialisation of resminostat in all oncological

  • Pharma deals during September 2013 Pharma deals during September 2013

    The lead pipeline candidates are SGI-110, a subcutaneous hypomethylating agent in multiple studies for a variety of haematological and solid tumour oncology indications, including MDS, AML, ovarian cancer and liver ... cancer, and AT13387, a second

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest from PMHub

  • 90TEN nominated for five Communiqué Awards

    Meanwhile two of the agency’s campaigns for Sirtex - in collaboration with Denovo Strategy - in metastatic colorectal liver cancer are shortlisted, for Excellence in Media Relations and Excellence in Integrated

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics